摘要
目的：观察康艾注射液联合TACE治疗原发性肝癌的疗效。方法将64例PLC患者随机分成两组各32例，观察组予康艾注射液联合TACE治疗，对照组单纯行TACE治疗。结果两组治疗后近期疗效总有效率无统计学差异(P >0.05)；观察组KPS 改善率明显高于对照组(P <0.05)；观察组不良反应(包括白细胞减少、血红蛋白下降、肝功能异常等)发生率低于对照组(P <0.05)。观察组治疗前后比较，CD3、CD4、NK 细胞活性升高(P <0.05)。结论康艾注射液联合TACE治疗PLC可改善患者生活质量,减轻毒副反应，调节免疫功能。
Abstract
Objective To observe the clinical efficacy of Ka-ng,ai injection combined with transcatheter arterial chem-oembolization(TACE) on Primary liver cancer(PLC). Methods 64 cases of primary liver cancer patients were randomly divided into two groups, the observation group(32 cases) received the Kang,ai injection treatment combined with TACE and the control group(32 cases) receive-ed TACE therapy only. Results The short-term efficacies of the observation group and the control group were 53.1% and 43.8%, respectively(P >0.05), with KPS improving rate 56.3% vs 31.3%(P <0.05). The occurrednce rate of adverse drug reaction such as leucopeni-a, hemoglobin decrease and liver function damage were lower in the observation group than that in the control group(P <0.05). The levels of CD3, CD4 and NK cells of the observation group increased after the treatment(P <0.05). Conclusion Kang,ai injection combined with TACE improves the life quailty of patients and decreases adverse reactions induced by TACE, at the same time, could adjust the patients,immune function.
NETL
NSTL
维普
万方数据